Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat-containing protein 91 (WDR91) is a WD40-repeat scaffold protein that functions as an essential effector of the small GTPase Rab7, playing a critical role in endosomal maturation by regulating the conversion between early and late endosomes[1][2][3][5]. It is specifically recruited to endosomal membranes through the interaction with active Rab7 and acts as a negative regulator of phosphatidylinositol 3-kinase (PI3K) activity, controlling levels of phosphatidylinositol 3-phosphate (PtdIns3P) to ensure proper endosomal maturation and trafficking[1][3][5]. WDR91 is a key part of the WDR81-WDR91 complex, which mediates efficient endolysosomal compartment fusion, thereby supporting the lysosomal degradation of surface receptors and endocytosed cargo[1]. Loss or dysfunction of WDR91 impairs endosomal transport and lysosomal degradation functions and is implicated in affecting neuronal development and associated with neurodegenerative phenotypes in genetic studies[1][5]. According to current data, WDR91 is not a direct therapeutic target, receptor, or enzyme, and there are no drugs or biomarkers currently known to interact with or act on WDR91[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat-containing protein 91 (WDR91).